Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer

Src tyrosine kinases are overexpressed in pancreatic cancers, and the oral Src inhibitor saracatinib has shown antitumor activity in preclinical models of pancreas cancer. We performed a CTEP-sponsored Phase II clinical trial of saracatinib in previously treated pancreas cancer patients, with a prim...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Arcaroli, John, Quackenbush, Kevin, Dasari, Arvind, Powell, Rebecca, McManus, Martine, Tan, Aik-Choon, Foster, Nathan R, Picus, Joel, Wright, John, Nallapareddy, Sujatha, Erlichman, Charles, Hidalgo, Manuel, Messersmith, Wells A
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2012
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3544442/
https://ncbi.nlm.nih.gov/pubmed/23342270
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.27
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados